https://www.nejm.org/doi/full/10.1056/NEJMcibr2113694
“It would therefore be prudent to fully characterize all antibody and T-cell responses to the virus and the vaccines, including Ab2 responses over time. Using huACE2 transgenic mice and crossing them with strains that are predisposed to autoimmunity or other human pathologic conditions can also provide important insights. An understanding of potential Ab2 responses may also provide insights into Ab1 maintenance and efficacy and into the application of antibody-based therapeutic agents. However, much more basic science research is needed to determine the potential role idiotype-based immunoregulation of both humoral and cell-mediated responses may play both in antiviral efficacy and in unwanted side effects of both SARS-CoV-2 infection and the vaccines that protect us from it.”
These animal studies should have been done prior to the jab going into any human, and probably were. Note that this article is not research per se, but just an opinion piece. It is, however, in the vaunted pages of the NEJM. TPTB must be trying to get out in front of this now. SHTF coming, methinks.
"We will collect viral load data from fresh fecal pellets. SARSr-CoV spike proteins will be sequenced, viral recombination events identified, and isolates used to deny strains that can replicate in human cells. The Univ. N Carolina (UNC) team will reverse engineer spike proteins of a large sample of high and low-risk viruses for further characterization. This will effectively freeze the QS we analyze at t=0. These QS0 strain viral spike glycoproteins will be synthesized and those binding to human cell receptor ACE2 will be inserted into SARSr-CoV backbones (non DURC, non-GoF), and inoculated into humanized mice to assess capacity o cause SARS like disease, efficay of monoclonal therapies, the inhibitor G-57348 or vaccines against SARS-Cov8-12. "
https://s3.documentcloud.org/documents/21066966/defuse-proposal.pdf